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A RANDOMISED, DOUBLE BLIND, PLACEBO CON-
TROLLED SINGLE ASCENDING DOSE STUDY OF PYM50018,
WITH AN OPEN LABEL CROSS-OVER STAGE TO ASSESS
FOOD EFFECT. D. H. Wessels, MBChB, MBA, R. Grover, FRCA,
A. Frend, PhD, S. Levene, FRCPCH, L. Potgieter, PhD, PAREXEL
CPRU, Phytopharm PLC, BioDynamics Research Limited,
FARMOVS-PAREXEL, London, United Kingdom.
BACKGROUND AND AIMS: PYM50018 has neuroprotective
properties and an emerging safety profile that make it a promising
candidate for the treatment of neurodegenerative disorders, such as
amyotrophic lateral sclerosis. This study evaluated the pharmacoki-
netics, safety and tolerability of the compound, together with the
effect of food on its bioavailability.
METHODS: Forty healthy males 18 to 45 years who met the
entry criteria were included. Four groups of ten subjects were ran-
domly allocated to receive placebo (n2) or PYM50018 (n8; 80
mg, 240 mg, 480 mg or 960 mg). One group also received
PYM50018 (240 mg) on two further occasions either after breakfast
or fasted.
RESULTS: Exposure to PYM50018 increased proportionately
with dose. At higher exposures a second, slower elimination phase
became apparent. Exposure to PYM50018 was increased after a high
fat breakfast, as compared with the fasted state. There were no
clinically significant changes in the safety parameters or adverse
events.
CONCLUSIONS: PYM50018 is well tolerated by healthy male
subjects as a single oral dose of up to 960 mg. Systemic exposure to
oral PYM50018 is dose proportional. Food has a significant effect on
the absorption kinetics of PYM50018.
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ACUTE EFFECTS OF CIGARETTE SMOKING ON GLOBAL
CEREBRAL BLOOD FLOW (GCBF) IN OVERNIGHT ABSTI-
NENT TOBACCO SMOKERS. T. Shinohara, K. Nagata, E.
Yokoyama, MD, M. Sato, MD, S. Matsuoka, I. Kanno, J. Hatazawa,
E. F. Domino, MD, Research Institute for Brain and Blood Vessels,
Showa Hospital, University of Michigan, Ann Arbor, MI.
BACKGROUND/AIMS: The acute effects of tobacco smoking
on gCBF were studied.
METHODS: Positron emission tomography (PET) with H215O
was used to measure quantitatively CBF in 10 right handed male
volunteer tobacco smokers. After 12 hr abstinence, gCBF measure-
ments (baseline, 5% CO2/95% O2, and cigarette smoking) were
made. gCBF was adjusted based on the vascular reactivity to CO2
and PaCO2 during smoking.
RESULTS: Mean gCBF during smoking compared with baseline
did not change. However, an increase in nicotine arterial plasma
correlated inversely with gCBF; gCBF increased in seven, decreased
in seven, and was unchanged in five sessions. gCBF increased during
smoking when baseline gCBF was low, whereas gCBF decreased
when baseline gCBF was high.
CONCLUSIONS: Individual differences suggest important bi-
modal effects of smoking on the brains of different tobacco smokers.
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DISPOSITION OF NICOTINE AND COTININE IN RAT
BLOOD AND BRAIN TISSUE, AND THEIR EFFECTS ON STRI-
ATAL CONCENTRATIONS OF DOPAMINE AND SEROTONIN.
Y. L. Chang, PhD, P. L. Tsai, PhD, L. C. Hung, BS, Y. C. Chou, PhD,
J. H. Tien, MS, T. H. Tsai, PhD, Department of Pharmacy, Taipei
Veterans General Hospital, Institute of Traditional Medicine, Na-
tional Yang-Ming University, National Research Institute of Chinese
Medicine, Taipei, Taiwan.
BACKGROUND: Concentrations of nicotine and cotinine fol-
lowing peripheral administration of nicotine to rats were determined
to assess nicotine disposition in both brain and blood. The feasibility
of microdialysis coupled with liquid chromatography system for
direct analysis of neurotransmitters in the rat striatum was investi-
gated. The purposes of the present study were to elucidate the
pharmacokinetics of nicotine and evaluate their effects on brain
dopaminergic and serotonergic neurotransmission in rat brain.
METHODS: We coupled a microdialysis sampling with on-line
automatic analysis chromatographic system to characterize the phar-
macokinetics of both nicotine and cotinine. The electrochemical
detection system was employed to determine the striatal dialysates
which included dopamine, serotonin and their respective metabolites
after i.v. administration of nicotine.
RESULTS AND CONCLUSIONS: The results showed nicotine
is easy to distribute into the central nervous system. Both drug levels
and AUC of nicotine in brain were significantly higher than those in
blood. On the other hand, levels of dopamine and serotonin had no
significant change compared to baseline after nicotine administration.
DOPAC are elevated than baseline in about 100 min interval. Con-
centrations of both HVA and 5-HIAA were consistently higher than
baseline levels. The results showed nicotine have significant impacts
on both dopaminergic and serotonergic neurotransmission in rat
brain.
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PATIENT SATISFACTION WITH TRANSDERMAL OXYBU-
TYNIN: INTERIM RESULTS FROM THE MATRIX STUDY. R.
Goldberg, MD, MPH, P. Sand, MD, N. Dahl, T. Lackner, PharmD,
Northwestern University, Watson Pharma, Inc., University of Min-
nesota, Evanston, IL.
BACKGROUND/AIMS: Transdermal oxybutynin (OXY-TDS)
has been proven safe and effective in treating overactive bladder
(OAB), with a low incidence of anticholinergic AEs. The anticho-
linergic AE profiles of oral agents may compromise persistence. We
have initiated a study to evaluate QoL, safety, pt satisfaction, and
persistence in OAB pts on OXY-TDS.
METHODS: The Multicenter Assessment of Transdermal Ther-
apy in Overactive Bladder with OXY-TDS (MATRIX study), an
open-label, randomized, long-term, multicenter, prospective study, is
to enroll 2500 community-dwelling adults. Pt-centered outcomes
include persistence, tolerability, QoL, personal well-being, mood,
social functioning, and activities of daily living. Validated question-
naires administered at baseline, 3 and 6 mos. Pt satisfaction data
captured monthly via outbound calls.
RESULTS: Currently 676 pts are enrolled. Mean age is 62.4 y
(21% 75 y); 86% female, 85% Caucasian. Of pts enrolled, 186 had
been on therapy for 1 mo. Of these, 80% found the patch to be
convenient; 78% were satisfied with ease of application; 36% felt the
patch offers benefits over previous OAB pharmacotherapy, including
effectiveness (33%), tolerability (34%), and ease of application
(37%).
CONCLUSIONS: Preliminary results provide positive pt feed-
back on OXY-TDS. Pts are satisfied with treatment and feel it offers
benefits over previous OAB treatments.
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